Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ivacaftor for cystic fibrosis: An evaluation of real world utilisation and expenditure in the Irish Healthcare Setting.

Irish medical journal - 12 Aug 2017

Corcoran A, Hickey N, Barry M, Usher C, McCullagh L M

Abstract excerpt

In Ireland, Ivacaftor is reimbursed, on the High-Tech Drug Scheme, for the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation. The aim of this study was to analyse the utilisation and expenditure of Ivacaftor on this scheme in the 12 month period post-reimbursement. All patients who had received Ivacaftor (regardless of General Medical Services Scheme...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Child
Share to Cystic Fibrosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Forced Expiratory Volume

Share to Ireland

Share to Quinolones

Share to Young Adult

Source

Identifiers

PMID: 29169001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ivacaftor for cystic fibrosis: An evaluation of real world utilisation and expenditure in the Irish Healthcare Setting.PMID 29169001Read ↗

Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis.Semantic proximity Read ↗

Tezacaftor-ivacaftor use in routine care of adults with cystic fibrosis: a medicine use evaluation.Semantic proximity Read ↗

Treatment patterns in people with cystic fibrosis: have they changed since the introduction of ivacaftor?Semantic proximity Read ↗

Rate of Uptake of Ivacaftor Use after U.S. Food and Drug Administration Approval among Patients Enrolled in the U.S. Cystic Fibrosis Foundation Patient Registry.Semantic proximity Read ↗

VOCAL: An observational study of ivacaftor for people with cystic fibrosis and selected non-G551D-CFTR gating mutations.Semantic proximity Read ↗

Longitudinal effects of ivacaftor and medicine possession ratio in people with the Gly551Asp mutation: a 5-year study.Semantic proximity Read ↗

Registry-based study in people with cystic fibrosis and an R117H variant treated with ivacaftor.Semantic proximity Read ↗

Real-world impact of ivacaftor in people with cystic fibrosis and select ivacaftor-responsive mutations.Semantic proximity Read ↗

Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease.Semantic proximity Read ↗

Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.Semantic proximity Read ↗

The U.S. Food and Drug Administration's Experience with Ivacaftor in Cystic Fibrosis. Establishing Efficacy Using In Vitro Data in Lieu of a Clinical Trial.Semantic proximity Read ↗

Ivacaftor: Five-year outcomes in the West of Scotland cystic fibrosis population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.